US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
22.02
+0.18 (+0.82%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Collegium Pharmaceutical, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
3 Healthcare Stocks That Concern Us
September 30, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Via
StockStory
3 Value Stocks That Fall Short
September 28, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via
StockStory
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
September 22, 2026
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether...
Via
StockStory
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
September 21, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
Topics
Stocks
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance
↗
August 06, 2026
Via
Chartmill
Collegium to Participate in Upcoming Investor Conferences
September 08, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Jornay PM revenue surged 41% as Collegium integrated Azstarys and expanded its sales force.
Via
The Motley Fool
Topics
Earnings
Collegium Announces $50 Million Accelerated Share Repurchase Program
August 13, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
August 13, 2026
Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Man...
Via
StockStory
Topics
Earnings
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
August 07, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ...
Via
StockStory
Collegium Pharmaceutical Q2 Earnings Call Highlights
↗
August 06, 2026
Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower...
Via
MarketBeat
Topics
Earnings
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
August 06, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ...
Via
StockStory
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
August 06, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
August 04, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to look for. Collegium ...
Via
StockStory
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks
July 23, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
July 20, 2026
New headquarters reflects Collegium's long-term vision and commitment to Massachusetts
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
1 Healthcare Stock with Competitive Advantages and 2 We Question
July 16, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial ...
Via
StockStory
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
July 07, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
1 Mooning Stock to Own for Decades and 2 That Underwhelm
July 03, 2026
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Via
StockStory
2 Profitable Stocks to Keep an Eye On and 1 We Brush Off
July 02, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
3 of Wall Street’s Favorite Stocks We Approach with Caution
June 19, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via
StockStory
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
2 Reasons to Sell COLL and 1 Stock to Buy Instead
June 03, 2026
Shareholders of Collegium Pharmaceutical would probably like to forget the past six months even happened. The stock dropped 36.3% and now trades at $30.47. T...
Via
StockStory
Topics
Supply Chain
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
May 27, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
3 Growth Stocks We’re Skeptical Of
May 26, 2026
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Via
StockStory
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
May 14, 2026
Collegium Pharmaceutical’s first quarter was marked by solid execution and positive market reaction, supported by robust growth in its ADHD and pain manageme...
Via
StockStory
Topics
Earnings
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
May 13, 2026
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...
Via
StockStory
Topics
Economy
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
May 12, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
May 11, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
Next >
